Daniel Zelterman, PhD

• Abhijit Patel
• Amer Zeidan
• Andrea Silber
• Anna Wurtz
• Anne Chiang
• Barbara Burtness
• Christos Hatzis
• Curtis Jamison Perry
• Cynthia Brandt
• Daniel Boffa
• David Rimm
• Denise Esserman
• Diane Krause
• Douglas E Brash
• Edward Kaftan
• Erin Hofstatter
• Frank Detterbeck
• Gail Anderson
• Geliang Gan
• Harriet Kluger
• Heping Zhang
• Jean Bolognia
• Jeanne Hendrickson
• Jeremy Kortmansky
• Joan K Monin
• John D Roberts
• Katerina Politi
• Kenneth B. Roberts
• Kurt Schalper
• Lauren Hachmann Sansing
• Lauretta Grau
• Lesley Devine
• Lohith Gowda
• Lucia Jilaveanu
• Lynn D. Wilson
• Lynn Tanoue
• Manoj M Pillai
• Mario Sznol
• Michael DiGiovanna
• Michael Kane
• Michal Marczyk
• Nikolai Podoltsev
• Noffar Bar
• Octavian Henegariu
• Ondrej Blaha
• Pei Hui
• Perry Miller
• Pieter Joost Van Wattum
• Prajwal Boddu
• Prakash Nadkarni
• Raisa Balbuena-Merle
• Robert Heimer
• Robert Tigelaar
• Roy S. Herbst
• Sarah Goldberg
• Scott Gettinger
• Shrikant Mane
• Stephan Ariyan
• Stuart Seropian
• Terri Parker
• Theodore Holford
• Wei Wei
• Zhe Jay Chen

Acquired Immunodeficiency Syndrome; Epidemiology; Genetics; Computational Biology; Statistics; Biomarkers, Pharmacological; Biostatistics

Bioinformatics; Biomarkers; Cancer; Genetics, Genomics, Epigenetics; HIV/AIDS; Modeling

• AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancersAbu-Khalaf M, Alex Hodge K, Hatzis C, Baldelli E, El Gazzah E, Valdes F, Sikov W, Mita M, Denduluri N, Murphy R, Zelterman D, Liotta L, Dunetz B, Dunetz R, Petricoin E, Pierobon M. AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers. Npj Precision Oncology 2023, 7: 18. PMID: 36797347, PMCID: PMC9935518, DOI: 10.1038/s41698-023-00360-5.
• Implicit and Explicit Dehumanization of Older Family Members: Novel Determinants of Elder Abuse ProclivityChang E, Monin J, Isenberg N, Zelterman D, Levy B. Implicit and Explicit Dehumanization of Older Family Members: Novel Determinants of Elder Abuse Proclivity. Stigma And Health 2023, 8: 40-48. PMID: 37092028, PMCID: PMC10120856, DOI: 10.1037/sah0000370.
• Regression methods for the appearances of extremes in climate dataYu C, Blaha O, Kane M, Wei W, Esserman D, Zelterman D. Regression methods for the appearances of extremes in climate data. Environmetrics 2022, 33 DOI: 10.1002/env.2764.
• Handbook of Statistical Methods for Randomized Controlled Clinical TrialsZelterman D. Handbook of Statistical Methods for Randomized Controlled Clinical Trials. Technometrics 2022, 64: 424-425. DOI: 10.1080/00401706.2022.2091872.
• Bayesian local exchangeability design for phase II basket trialsLiu Y, Kane M, Esserman D, Blaha O, Zelterman D, Wei W. Bayesian local exchangeability design for phase II basket trials. Statistics In Medicine 2022, 41: 4367-4384. PMID: 35777367, PMCID: PMC10279458, DOI: 10.1002/sim.9514.
• Applied Multivariate Statistics with RZelterman D. Applied Multivariate Statistics with R. 2022 DOI: 10.1007/978-3-031-13005-2.
• Dehumanization of Older Family Members: Novel Determinants of Elder Abuse Proclivity by CaregiversChang E, Monin J, Zelterman D, Isenberg N, Levy B. Dehumanization of Older Family Members: Novel Determinants of Elder Abuse Proclivity by Caregivers. Innovation In Aging 2021, 5: 320-321. PMCID: PMC8680248, DOI: 10.1093/geroni/igab046.1250.
• Structural and Individual Ageism Predicts Elder Abuse Proclivity and PerpetrationChang E, Monin J, Zelterman D, Levy B. Structural and Individual Ageism Predicts Elder Abuse Proclivity and Perpetration. Innovation In Aging 2021, 5: 88-89. PMCID: PMC8680997, DOI: 10.1093/geroni/igab046.338.
• Impact of Structural Ageism on Greater Violence Against Older Persons: A Cross-National Study of 56 CountriesChang E, Monin J, Zelterman D, Levy B. Impact of Structural Ageism on Greater Violence Against Older Persons: A Cross-National Study of 56 Countries. Innovation In Aging 2021, 5: 179-179. PMCID: PMC8969772, DOI: 10.1093/geroni/igab046.683.
• Unified exact design with early stopping rules for single arm clinical trials with multiple endpointsWei W, Esserman D, Kane M, Zelterman D. Unified exact design with early stopping rules for single arm clinical trials with multiple endpoints. Statistical Methods In Medical Research 2021, 30: 1575-1588. PMID: 34159859, PMCID: PMC8959087, DOI: 10.1177/09622802211013062.
• A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1Weiss SA, Djureinovic D, Jessel S, Krykbaeva I, Zhang L, Jilaveanu L, Ralabate A, Johnson B, Levit NS, Anderson G, Zelterman D, Wei W, Mahajan A, Trifan O, Bosenberg M, Kaech SM, Perry CJ, Damsky W, Gettinger S, Sznol M, Hurwitz M, Kluger HM. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1. Clinical Cancer Research 2021, 27: 4757-4767. PMID: 34140403, PMCID: PMC9236708, DOI: 10.1158/1078-0432.ccr-21-0903.
• Impact of structural ageism on greater violence against older persons: a cross-national study of 56 countriesChang ES, Monin JK, Zelterman D, Levy BR. Impact of structural ageism on greater violence against older persons: a cross-national study of 56 countries. BMJ Open 2021, 11: e042580. PMID: 33986041, PMCID: PMC8126306, DOI: 10.1136/bmjopen-2020-042580.
• Abstract PS5-28: Multiomic advanced diagnostics for CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancerAbu-Khalaf M, Hatzis C, Hodge K, Valdes F, Sikov W, Mita M, Denduluri N, Awerkamp K, Murphy R, Zelterman D, Dunetz B, Petricoin E, Pierobon M. Abstract PS5-28: Multiomic advanced diagnostics for CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer. Cancer Research 2021, 81: ps5-28-ps5-28. DOI: 10.1158/1538-7445.sabcs20-ps5-28.
• Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML)Zeidan A, Boddu P, Wood B, Zelterman D, Little R, Ivy S, Caldwell A, Sanchez-Espiridion B, Alatrash G, Sharon E, Radich J. Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML). Blood 2020, 136: 15. DOI: 10.1182/blood-2020-139668.
• Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive ChemotherapyZeidan A, Boddu P, Wood B, Zelterman D, Little R, Ivy S, Caldwell A, Sanchez-Espiridion B, Alatrash G, Sharon E, Radich J. Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy. Blood 2020, 136: 11-12. DOI: 10.1182/blood-2020-139752.
• Distributions associated with simultaneous multiple hypothesis testingYu C, Zelterman D. Distributions associated with simultaneous multiple hypothesis testing. Journal Of Statistical Distributions And Applications 2020, 7: 9. DOI: 10.1186/s40488-020-00109-6.
• CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer for treatment selection and response prediction.Abu-Khalaf M, Hatzis C, Hodge K, Valdes F, Sikov W, Mita M, Denduluri N, Awerkamp K, Murphy R, Zelterman D, Dunetz B, Petricoin E, Pierobon M. CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer for treatment selection and response prediction. Journal Of Clinical Oncology 2020, 38: e13029-e13029. DOI: 10.1200/jco.2020.38.15_suppl.e13029.
• Abstract P5-13-02: Neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and an oncotype Dx recurrence score (≤25)Abu-Khalaf M, Aderhold K, Marczyk M, Chung G, Hofstatter E, Sanft T, Silber A, DiGiovanna M, Zelterman D, Puzstai L, Hatzis C. Abstract P5-13-02: Neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and an oncotype Dx recurrence score (≤25). Cancer Research 2020, 80: p5-13-02-p5-13-02. DOI: 10.1158/1538-7445.sabcs19-p5-13-02.
• Allogeneic Stem Cell Transplantation for T-Cell Lymphomas in the Modern Era: A Single Center ExperienceBoddu P, Perreault S, Isufi I, Chandhok N, Kim T, Pillai M, Bar N, Prebet T, Zeidan A, Zelterman D, Seropian S, Gowda L, Foss F. Allogeneic Stem Cell Transplantation for T-Cell Lymphomas in the Modern Era: A Single Center Experience. Transplantation And Cellular Therapy 2019, 25: s387. DOI: 10.1016/j.bbmt.2018.12.796.
• Abstract OT3-02-06: Utilizing multiomic advanced diagnostics to identify CDK4/6 inhibitor response predictors and a post-treatment multiomic signature for patients with ER+/HER2- metastatic breast cancer (SIDEOUT-3)Abu-Khalaf M, Pierobon M, Denduluri N, Valdes-Albini F, Forero-Torres A, Clark A, Yung R, Mita M, Christensen S, Awerkamp K, Dunetz B, Murphy R, Hatzis C, Zelterman D, Liotta L, Petricoin E. Abstract OT3-02-06: Utilizing multiomic advanced diagnostics to identify CDK4/6 inhibitor response predictors and a post-treatment multiomic signature for patients with ER+/HER2- metastatic breast cancer (SIDEOUT-3). Cancer Research 2019, 79: ot3-02-06-ot3-02-06. DOI: 10.1158/1538-7445.sabcs18-ot3-02-06.
• Elevated Levels of CD64 MFI on Monocyte Subsets Are Associated with a History of Stroke in Sickle Cell DiseaseCurtis S, Balbuena-Merle R, Devine L, Zelterman D, Roberts J, Dearborn-Tomazos J, Sansing L, Hendrickson J. Elevated Levels of CD64 MFI on Monocyte Subsets Are Associated with a History of Stroke in Sickle Cell Disease. Blood 2018, 132: 1093. DOI: 10.1182/blood-2018-99-117504.
• Differential outcomes in patients with uncommon EGFR exon 19 mutations.Stewart T, Truini A, DeVeaux M, Zelterman D, Walther Z, Wurtz A, Gettinger S, Politi K, Goldberg S. Differential outcomes in patients with uncommon EGFR exon 19 mutations. Journal Of Clinical Oncology 2018, 36: 9056-9056. DOI: 10.1200/jco.2018.36.15_suppl.9056.
• 2168Branagan A, Duffy E, Parker T, Seropian S, Foster C, Zhang L, Verma R, Gan G, Zelterman D, Brandt D, Kortmansky J, Witt D, Dhodapkar M. 2168. Journal Of Clinical And Translational Science 2017, 1: 31-32. PMCID: PMC6799516, DOI: 10.1017/cts.2017.118.
• 1341P Assessing response to immunotherapy in patients with non-small cell lung cancer using circulating tumor DNAGoldberg S, Narayan A, Kole A, Decker R, Teysir J, Carriero N, Lee A, Nemati R, Nath S, Mane S, Deng Y, Sukumar N, Zelterman D, Boffa D, Politi K, Gettinger S, Wilson L, Herbst R, Patel A. 1341P Assessing response to immunotherapy in patients with non-small cell lung cancer using circulating tumor DNA. Annals Of Oncology 2017, 28: v478. DOI: 10.1093/annonc/mdx380.043.
• Abstract 2492: DNA polymerase beta participates in DNA end-joiningRay S, DeVeaux M, Breuer G, Bindra R, Zelterman D, Sweasy J. Abstract 2492: DNA polymerase beta participates in DNA end-joining. Cancer Research 2017, 77: 2492-2492. DOI: 10.1158/1538-7445.am2017-2492.
• MA15.06 Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD-1 Axis Therapy in Non-Small Cell Lung Cancer (NSCLC)Gettinger S, Choi J, Mani N, Datar I, Kaftan E, Goldberg S, Zelterman D, Politi K, Lifton R, Rimm D, Herbst R, Schalper K. MA15.06 Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD-1 Axis Therapy in Non-Small Cell Lung Cancer (NSCLC). Journal Of Thoracic Oncology 2017, 12: s430-s431. DOI: 10.1016/j.jtho.2016.11.501.
• P3.02c-048 A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC Topic: ITDecker R, Goldberg S, Nath S, Husain Z, Lilenbaum R, Schalper K, Chiang A, Altan M, Zelterman D, Kaech S, Herbst R, Gettinger S. P3.02c-048 A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC Topic: IT. Journal Of Thoracic Oncology 2017, 12: s1303-s1304. DOI: 10.1016/j.jtho.2016.11.1843.
• Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical TrialBranagan A, Duffy E, Parker T, Seropian S, Foster C, Zhang L, Verma R, Zelterman D, Gan G, Brandt D, Kortmansky J, Witt D, Ferencz T, Dhodapkar M. Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial. Blood 2016, 128: 2139. DOI: 10.1182/blood.v128.22.2139.2139.
• The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient CohortStahl M, Podoltsev N, DeVeaux M, Perreault S, Itzykson R, Ritchie E, Sekeres M, Fathi A, Komrokji R, Bhatt V, Al-Kali A, Cluzeau T, Santini V, Brunner A, Roboz G, Fenaux P, Litzow M, Vey N, Verma V, Germing U, Fernández P, Zelterman D, Kim T, Prebet T, Gore S, Zeidan A. The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort. Blood 2016, 128: 1063. DOI: 10.1182/blood.v128.22.1063.1063.
• Estrogen withdrawal, breast cell transformation, and multiple breast cancer risk in women with the KRAS-variant.Weidhaas J, McVeigh T, Jung S, Salzman D, Nallur S, Dookwah M, Nemec A, Sadofsky J, Paranjape T, Kelly O, Chan E, Miller N, Sweeney K, Zelterman D, Sweasy J, Pilarski R, Telesca D, Kerin M. Estrogen withdrawal, breast cell transformation, and multiple breast cancer risk in women with the KRAS-variant. Journal Of Clinical Oncology 2015, 33: e12541-e12541. DOI: 10.1200/jco.2015.33.15_suppl.e12541.
• Applied Multivariate Statistics with RZelterman D. Applied Multivariate Statistics with R. 2015 DOI: 10.1007/978-3-319-14093-3.
• A Groaning DemographicZelterman D. A Groaning Demographic. Significance 2014, 11: 38-43. DOI: 10.1111/j.1740-9713.2014.00783.x.
• Multinomial Distribution: OverviewZelterman D. Multinomial Distribution: Overview. 2014 DOI: 10.1002/9781118445112.stat04877.
• Processing length bias of time intervals between the last episode and the interview in Gamma-Poisson models of behaviorZelterman D, Suvorova A, Paschenko A, Musina V, Tulupyev A, Tulupyeva T, Krasnoselskikh T, Grau L, Heimer R. Processing length bias of time intervals between the last episode and the interview in Gamma-Poisson models of behavior. SPIIRAS Proceedings 2014, 1: 160-185. DOI: 10.15622/sp.16.6.
• Regression diagnostics in the rate analysis based on data about the last episodesZelterman D, Suvorova A, Paschenko A, Musina V, Tulupyev A, Tulupyeva T, Grau L, Heimer R. Regression diagnostics in the rate analysis based on data about the last episodes. SPIIRAS Proceedings 2014, 2: 33-46. DOI: 10.15622/sp.17.2.
• Beta prime regression with application to risky behavior frequency screeningTulupyev A, Suvorova A, Sousa J, Zelterman D. Beta prime regression with application to risky behavior frequency screening. Statistics In Medicine 2013, 32: 4044-4056. PMID: 23616229, PMCID: PMC3789864, DOI: 10.1002/sim.5820.
• The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian CancerPilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, McKenna M, Wu X, Hildebrandt M, Zelterman D, Sand S, Shulman LP. The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer. PLOS ONE 2012, 7: e37891. PMID: 22662244, PMCID: PMC3360659, DOI: 10.1371/journal.pone.0037891.
• Association between KRAS rs61764370 and triple-negative breast cancer—a false positive? – Authors' replyWeidhaas J, Slack F, Miller N, Harris L, Tuck D, Zhu Y, Zelterman D, Kerin M, Paranjape T, Heneghan H, Lindner R, Keane F, Dorairaj J, Geyda K, Pelletier C, Nallur S. Association between KRAS rs61764370 and triple-negative breast cancer—a false positive? – Authors' reply. The Lancet Oncology 2011, 12: 724. DOI: 10.1016/s1470-2045(11)70163-2.
• Fructosamine reference ranges in rhesus macaques (Macaca mulatta).Williams-Fritze MJ, Smith PC, Zelterman D, Scholz JA. Fructosamine reference ranges in rhesus macaques (Macaca mulatta). Journal Of The American Association For Laboratory Animal Science 2011, 50: 462-5. PMID: 21838972, PMCID: PMC3148637.
• A phase II trial of gemcitabine (G), carboplatin (C), and sorafenib (S) in patients (pts) with transitional cell carcinoma (TCC): Preliminary safety and outcome.Mehnert J, Mortazavi A, Stein M, Donadio A, Zelterman D, McDonough J, Rowen E, Hoimes C, Gibney G, Kelly W. A phase II trial of gemcitabine (G), carboplatin (C), and sorafenib (S) in patients (pts) with transitional cell carcinoma (TCC): Preliminary safety and outcome. Journal Of Clinical Oncology 2011, 29: 278-278. DOI: 10.1200/jco.2011.29.7_suppl.278.
• Abstract P3-14-17: Trastuzumab (H) and Rapamycin (R) for Treatment of HER-2 Overexpressing Metastatic Breast Cancer (BC) with Prior Disease Progression on H Based Therapy: Safety and Pharmacodynamic (PD) ResultsAbu-Khalaf M, Chung G, DiGiovanna M, Fishbach N, Zelterman D, Tuck D, Harris L. Abstract P3-14-17: Trastuzumab (H) and Rapamycin (R) for Treatment of HER-2 Overexpressing Metastatic Breast Cancer (BC) with Prior Disease Progression on H Based Therapy: Safety and Pharmacodynamic (PD) Results. Cancer Research 2010, 70: p3-14-17-p3-14-17. DOI: 10.1158/0008-5472.sabcs10-p3-14-17.
• Postoperative Vaginal Cuff Brachytherapy Alone (VB) Provides Equally Effective Treatment with Less Toxicity Than External Beam Radiation and Vaginal Cuff Brachytherapy (EXT + VB) in the Treatment of Stage II Endometrial AdenocarcinomaGalper S, Harrington J, Ratner E, Deng Y, Zelterman D, Hui P, Rutherford T, Higgins S. Postoperative Vaginal Cuff Brachytherapy Alone (VB) Provides Equally Effective Treatment with Less Toxicity Than External Beam Radiation and Vaginal Cuff Brachytherapy (EXT + VB) in the Treatment of Stage II Endometrial Adenocarcinoma. International Journal Of Radiation Oncology • Biology • Physics 2010, 78: s415-s416. DOI: 10.1016/j.ijrobp.2010.07.978.
• Biostatistics: Principles and Practice. By B. Antonisamy, Solomon Christopher, and P. Prasanna Samuel New Delhi, India: Tata McGraw Hill, 2010. 349 pp. Illustrated. Rs 350 (softcover)Wormser G, Zelterman D. Biostatistics: Principles and Practice. By B. Antonisamy, Solomon Christopher, and P. Prasanna Samuel New Delhi, India: Tata McGraw Hill, 2010. 349 pp. Illustrated. Rs 350 (softcover). Clinical Infectious Diseases 2010, 51: 1112-1113. DOI: 10.1093/clinids/51.9.1112-a.
• Applied Linear Models with SASZelterman D. Applied Linear Models with SAS. 2010 DOI: 10.1017/cbo9780511778643.
• Abstract 3029: A KRAS microRNA binding site polymorphism as a novel biomarker of risk in triple negative breast cancerParanjape T, Heneghan H, Pelletier C, Hoffman A, Kerin M, Harris L, Zhu Y, Miller N, Zelterman D, Tuck D, Slack F, Weidhaas J. Abstract 3029: A KRAS microRNA binding site polymorphism as a novel biomarker of risk in triple negative breast cancer. Cancer Research 2010, 70: 3029-3029. DOI: 10.1158/1538-7445.am10-3029.
• Abstract 5324: Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesisChae W, Henegariu O, Zelterman D, Hao L, Gibson T, Bothwell A. Abstract 5324: Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Cancer Research 2010, 70: 5324-5324. DOI: 10.1158/1538-7445.am10-5324.
• Metachronous Primary Melanoma and LymphomaMcIntosh BC, Ariyan S, Esche G, Zelterman D, Narayan D. Metachronous Primary Melanoma and Lymphoma. Annals Of Plastic Surgery 2010, 64: 229-232. PMID: 20098111, DOI: 10.1097/sap.0b013e3181a13dbf.
• The Mechanism of Spontaneous Intestinal Tumorigenesis Via CD4 T Cell-derived IL-17AChae W, Gibson T, Zelterman D, Hao L, Henegariu O, Bothwell A. The Mechanism of Spontaneous Intestinal Tumorigenesis Via CD4 T Cell-derived IL-17A. Clinical Immunology 2010, 135: s62-s63. DOI: 10.1016/j.clim.2010.03.191.
• Effect of Community-Based Group Prenatal Physical Activity on Pre-eclampsia RateBrancato R, Cowlin A, Mor G, DeZinno P, Zelterman D. Effect of Community-Based Group Prenatal Physical Activity on Pre-eclampsia Rate. Medicine & Science In Sports & Exercise 2008, 40: s106-s107. DOI: 10.1249/01.mss.0000321913.16411.1b.
• Computational Bayesian inference for estimating the size of a finite populationNandram B, Zelterman D. Computational Bayesian inference for estimating the size of a finite population. Computational Statistics & Data Analysis 2007, 51: 2934-2945. DOI: 10.1016/j.csda.2006.11.034.
• In ReplyLally B, Zelterman D, Colasanto J, Haffty B, Detterbeck F, Wilson L. In Reply. Journal Of Clinical Oncology 2007, 25: 460-461. DOI: 10.1200/jco.2006.09.4771.
• In ReplyLally B, Zelterman D, Colasanto J, Haffty B, Detterbeck F, Wilson L. In Reply. Journal Of Clinical Oncology 2006, 24: 5612-5613. DOI: 10.1200/jco.2006.09.1819.
• 2052 A Phase II Trial of Mammosite Breast Brachytherapy Optimization in the Treatment of Stage 0, I and II Breast CarcinomaWeidhaas J, Ponn T, Chen Z, Martel M, Zelterman D. 2052 A Phase II Trial of Mammosite Breast Brachytherapy Optimization in the Treatment of Stage 0, I and II Breast Carcinoma. International Journal Of Radiation Oncology • Biology • Physics 2006, 66: s239. DOI: 10.1016/j.ijrobp.2006.07.455.
• Upregulation of thymidine phosphorylase (TP) by radiation (XRT): Phase II study of capecitabine (CAP) with XRT in pts with locally advanced (LA) pancreatic cancerRoy S, Russo S, Black G, Eloubeidi M, Steg A, Zelterman D, Johnson M, Diasio R, Saif M. Upregulation of thymidine phosphorylase (TP) by radiation (XRT): Phase II study of capecitabine (CAP) with XRT in pts with locally advanced (LA) pancreatic cancer. Journal Of Clinical Oncology 2006, 24: 14001-14001. DOI: 10.1200/jco.2006.24.18_suppl.14001.
• Postoperative Radiotherapy for Stage II or III Non–Small-Cell Lung Cancer Using the Surveillance, Epidemiology, and End Results DatabaseLally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative Radiotherapy for Stage II or III Non–Small-Cell Lung Cancer Using the Surveillance, Epidemiology, and End Results Database. Journal Of Clinical Oncology 2006, 24: 2998-3006. PMID: 16769986, DOI: 10.1200/jco.2005.04.6110.
• An occupancy distribution arising in a limiting dilution assay for HIV-1Zelterman D. An occupancy distribution arising in a limiting dilution assay for HIV-1. Statistics & Probability Letters 2006, 76: 1-9. DOI: 10.1016/j.spl.2005.06.016.
• Validation of the European Organization for Research and Treatment of Cancer (EORTC) Prognostic Factors for Low Grade Gliomas Utilizing the Surveillance, Epidemiology, and End Results (SEER) DatabaseKnisely J, Lally B, Zelterman D. Validation of the European Organization for Research and Treatment of Cancer (EORTC) Prognostic Factors for Low Grade Gliomas Utilizing the Surveillance, Epidemiology, and End Results (SEER) Database. International Journal Of Radiation Oncology • Biology • Physics 2005, 63: s262-s263. DOI: 10.1016/j.ijrobp.2005.07.449.
• Weighted Binomial Distributions and Disease ClustersZelterman D. Weighted Binomial Distributions and Disease Clusters. 2005, 209-241. DOI: 10.1002/0470868902.ch8.
• Maximum Negative Binomial DistributionZelterman D. Maximum Negative Binomial Distribution. 2005, 25-56. DOI: 10.1002/0470868902.ch2.
• Frequency Models for Family Disease Clusters Zelterman D. Frequency Models for Family Disease Clusters . 2005, 141-172. DOI: 10.1002/0470868902.ch6.
• IntroductionZelterman D. Introduction. 2005, 1-24. DOI: 10.1002/0470868902.ch1.
• Multivariate Distributions for TwinsZelterman D. Multivariate Distributions for Twins. 2005, 103-140. DOI: 10.1002/0470868902.ch5.
• Applications to Teratology ExperimentsZelterman D. Applications to Teratology Experiments. 2005, 243-264. DOI: 10.1002/0470868902.ch9.
• The Maximum Negative Hypergeometric DistributionZelterman D. The Maximum Negative Hypergeometric Distribution. 2005, 57-76. DOI: 10.1002/0470868902.ch3.
• Sums of Dependent Bernoulli's and Disease ClustersZelterman D. Sums of Dependent Bernoulli's and Disease Clusters. 2005, 173-208. DOI: 10.1002/0470868902.ch7.
• Univariate Discrete Distributions for Use with TwinsZelterman D. Univariate Discrete Distributions for Use with Twins. 2005, 77-101. DOI: 10.1002/0470868902.ch4.
• Multinomial DistributionZelterman D. Multinomial Distribution. 2005 DOI: 10.1002/0470011815.b2a10038.
• Bayesian Artificial IntelligenceZelterman D. Bayesian Artificial Intelligence. Technometrics 2005, 47: 101-102. DOI: 10.1198/tech.2005.s836.
• Discrete DistributionsZelterman D. Discrete Distributions. 2004 DOI: 10.1002/0470868902.
• Diagnostics for the Accelerated Life Time Model of Survival DataZelterman D, Lin H. Diagnostics for the Accelerated Life Time Model of Survival Data. 2003, 23: 443-459. DOI: 10.1016/s0169-7161(03)23025-x.
• Statistical Inference for Familial Disease ClustersYu C, Zelterman D. Statistical Inference for Familial Disease Clusters. Biometrics 2002, 58: 481-491. PMID: 12229982, DOI: 10.1111/j.0006-341x.2002.00481.x.
• Rank tests of association for exchangeable paired dataLi J, Zelterman D. Rank tests of association for exchangeable paired data. Computational Statistics & Data Analysis 2002, 40: 111-129. DOI: 10.1016/s0167-9473(01)00096-2.
• Sums of dependent Bernoulli random variables and disease clusteringYu C, Zelterman D. Sums of dependent Bernoulli random variables and disease clustering. Statistics & Probability Letters 2002, 57: 363-373. DOI: 10.1016/s0167-7152(02)00091-3.
• Modeling Survival Data: Extending the Cox ModelLin H, Zelterman D. Modeling Survival Data: Extending the Cox Model. Technometrics 2002, 44: 85-86. DOI: 10.1198/tech.2002.s656.
• Escaping the stem cell compartment: Sustained UVB exposure allows p53-mutant keratinocytes to colonize adjacent epidermal proliferating units without incurring additional mutationsZhang W, Remenyik E, Zelterman D, Brash D, Wikonkal N. Escaping the stem cell compartment: Sustained UVB exposure allows p53-mutant keratinocytes to colonize adjacent epidermal proliferating units without incurring additional mutations. Proceedings Of The National Academy Of Sciences Of The United States Of America 2001, 98: 13948-13953. PMID: 11707578, PMCID: PMC61147, DOI: 10.1073/pnas.241353198.
• The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.Peng X, Won J, Rutherford T, Fujii T, Zelterman D, Pizzorno G, Sapi E, Leavitt J, Kacinski B, Crystal R, Schwartz P, Deisseroth A. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. Cancer Research 2001, 61: 4405-13. PMID: 11389068.
• Causality: Models, Reasoning, and InferenceZelterman D. Causality: Models, Reasoning, and Inference. Technometrics 2001, 43: 239-240. DOI: 10.1198/tech.2001.s594.
• EXACT INFERENCE FOR FAMILY DISEASE CLUSTERSYu C, Zelterman D. EXACT INFERENCE FOR FAMILY DISEASE CLUSTERS. Communication In Statistics- Theory And Methods 2001, 30: 2293-2305. DOI: 10.1081/sta-100107686.
• Patterns of response to acute naloxone infusion in Tourette's syndromevan Wattum P, Chappell P, Zelterman D, Scahill L, Leckman J. Patterns of response to acute naloxone infusion in Tourette's syndrome. Movement Disorders 2000, 15: 1252-1254. PMID: 11104215, DOI: 10.1002/1531-8257(200011)15:6<1252::aid-mds1030>3.0.co;2-i.
• Granulocyte-Macrophage Colony-Stimulating Factor Priming plus Papillomavirus E6 DNA Vaccination: Effects on Papilloma Formation and Regression in the Cottontail Rabbit Papillomavirus-Rabbit ModelLeachman S, Tigelaar R, Shlyankevich M, Slade M, Irwin M, Chang E, Wu T, Xiao W, Pazhani S, Zelterman D, Brandsma J. Granulocyte-Macrophage Colony-Stimulating Factor Priming plus Papillomavirus E6 DNA Vaccination: Effects on Papilloma Formation and Regression in the Cottontail Rabbit Papillomavirus-Rabbit Model. Journal Of Virology 2000, 74: 8700-8708. PMID: 10954571, PMCID: PMC116381, DOI: 10.1128/jvi.74.18.8700-8708.2000.
• Numerical Analysis for StatisticiansZelterman D. Numerical Analysis for Statisticians. Technometrics 2000, 42: 322-322. DOI: 10.1080/00401706.2000.10486074.
• The maximum negative binomial distributionZhang Z, Burtness B, Zelterman D. The maximum negative binomial distribution. Journal Of Statistical Planning And Inference 2000, 87: 1-19. DOI: 10.1016/s0378-3758(99)00177-9.
• Binary Regression for Risks in Excess of Subject-Specific ThresholdsZhang H, Zelterman D. Binary Regression for Risks in Excess of Subject-Specific Thresholds. Biometrics 1999, 55: 1247-1251. PMID: 11315077, DOI: 10.1111/j.0006-341x.1999.01247.x.
• Follow‐up recommendations for patients with American Joint Committee on Cancer Stages I–III malignant melanomaPoo‐Hwu W, Ariyan S, Lamb L, Papac R, Zelterman D, Hu G, Brown J, Fischer D, Bolognia J, Buzaid A. Follow‐up recommendations for patients with American Joint Committee on Cancer Stages I–III malignant melanoma. Cancer 1999, 86: 2252-2258. PMID: 10590365, DOI: 10.1002/(sici)1097-0142(19991201)86:11<2252::aid-cncr12>3.0.co;2-q.
• Downregulation of p27KIP1 and Ki67/Mib1 Labeling Index Support the Classification of Thyroid Carcinoma Into Prognostically Relevant CategoriesTallini G, Garcia-Rostan G, Herrero A, Zelterman D, Viale G, Bosari S, Carcangiu M. Downregulation of p27KIP1 and Ki67/Mib1 Labeling Index Support the Classification of Thyroid Carcinoma Into Prognostically Relevant Categories. The American Journal Of Surgical Pathology 1999, 23: 678-685. PMID: 10366150, DOI: 10.1097/00000478-199906000-00007.
• Functional activity of murine CD34+and CD34− hematopoietic stem cell populationsDonnelly D, Zelterman D, Sharkis S, Krause D. Functional activity of murine CD34+and CD34− hematopoietic stem cell populations. Experimental Hematology 1999, 27: 788-796. PMID: 10340393, DOI: 10.1016/s0301-472x(99)00032-6.
• Multivariate Discrete Models for Longevity in TwinsZelterman D, Yu C. Multivariate Discrete Models for Longevity in Twins. 1999, 114: 131-140. DOI: 10.1007/978-1-4612-1540-0_8.
• Assessment of Cardiac and Pulmonary Function in Adult Patients with Hodgkin's Disease Treated with ABVD or MOPP/ABVD Plus Adjuvant Low-Dose Mediastinal IrradiationSalloum E, Tanoue L, Wackers F, Zelterman D, Hu G, Cooper D. Assessment of Cardiac and Pulmonary Function in Adult Patients with Hodgkin's Disease Treated with ABVD or MOPP/ABVD Plus Adjuvant Low-Dose Mediastinal Irradiation. Cancer Investigation 1999, 17: 171-180. PMID: 10099655, DOI: 10.3109/07357909909021418.
• Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantationSalloum E, Jillella A, Nadkarni R, Seropian S, Hu G, D'Andrea E, Zelterman D, Cooper D. Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation. Cancer 1998, 82: 1506-1512. PMID: 9554528, DOI: 10.1002/(sici)1097-0142(19980415)82:8<1506::aid-cncr12>3.0.co;2-8.
• Managing Attribute–Value Clinical Trials Data Using the ACT/DB Client–Server Database SystemNadkarni P, Brandt C, Frawley S, Sayward F, Einbinder R, Zelterman D, Schacter L, Miller P. Managing Attribute–Value Clinical Trials Data Using the ACT/DB Client–Server Database System. Journal Of The American Medical Informatics Association 1998, 5: 139-151. PMID: 9524347, PMCID: PMC61285, DOI: 10.1136/jamia.1998.0050139.
• 16 A semiparametric bootstrap for simulating extreme order statisticsStrawderman R, Zelterman D. 16 A semiparametric bootstrap for simulating extreme order statistics. 1998, 16: 441-462. DOI: 10.1016/s0169-7161(98)16018-2.
• Log-linear modeling with the negative multinomial distribution.Waller L, Zelterman D. Log-linear modeling with the negative multinomial distribution. Biometrics 1997, 53: 971-82. PMID: 9290226, DOI: 10.2307/2533557.
• A 40-year analysis of 265 gastric carcinoids.Modlin I, Sandor A, Tang L, Kidd M, Zelterman D. A 40-year analysis of 265 gastric carcinoids. The American Journal Of Gastroenterology 1997, 92: 633-8. PMID: 9128313.
• Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients.Salloum E, Brandt D, Caride V, Cornelius E, Zelterman D, Schubert W, Mannino T, Cooper D. Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients. Journal Of Clinical Oncology 1997, 15: 518-27. PMID: 9053473, DOI: 10.1200/jco.1997.15.2.518.
• Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation.Salloum E, Doria R, Schubert W, Zelterman D, Holford T, Roberts K, Farber L, Kiehl R, Cardinale J, Cooper D. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. Journal Of Clinical Oncology 1996, 14: 2435-43. PMID: 8823321, DOI: 10.1200/jco.1996.14.9.2435.
• Bootstrap techniques for proportional hazards models with censored observationsZelterman D, Le C, Louis T. Bootstrap techniques for proportional hazards models with censored observations. Statistics And Computing 1996, 6: 191-199. DOI: 10.1007/bf00140864.
• Tuberculosis in physicians: Compliance with surveillance and treatmentRamphal-Naley L, Kirkhorn S, Lohman W, Zelterman D. Tuberculosis in physicians: Compliance with surveillance and treatment. American Journal Of Infection Control 1996, 24: 243-253. PMID: 8870908, DOI: 10.1016/s0196-6553(96)90056-5.
• Exact Tests of Significance in Higher Dimensional TablesZelterman D, Chan I, Mielke P. Exact Tests of Significance in Higher Dimensional Tables. The American Statistician 1995, 49: 357-361. DOI: 10.1080/00031305.1995.10476182.
• Exact Tests of Significance in Higher Dimensional TablesZelterman D, Chan I, Mielke P. Exact Tests of Significance in Higher Dimensional Tables. The American Statistician 1995, 49: 357. DOI: 10.2307/2684573.
• Survival curves subjected to occasional insults.Zelterman D, Curtsinger J. Survival curves subjected to occasional insults. Biometrics 1995, 51: 1140-6. PMID: 7548697, DOI: 10.2307/2533013.
• Statistical Models for Causal AnalysisZelterman D. Statistical Models for Causal Analysis. Technometrics 1994, 36: 327-328. DOI: 10.1080/00401706.1994.10485822.
• Prevalence of microfissures in the human temporal bone: A report of 1000 temporal bonesMoreano E, Paparella M, Zelterman D, Goycoolea M. Prevalence of microfissures in the human temporal bone: A report of 1000 temporal bones. The Laryngoscope 1994, 104: 741-746. PMID: 8196450, DOI: 10.1288/00005537-199406000-00015.
• Topical CTC-96 accelerates wart growth in rabbits infected with cottontail rabbit papillomavirusOstrow R, Coughlin S, McGlennen R, Liu Z, Zelterman D, Faras A. Topical CTC-96 accelerates wart growth in rabbits infected with cottontail rabbit papillomavirus. Antiviral Research 1994, 24: 27-35. PMID: 7944311, DOI: 10.1016/0166-3542(94)90049-3.
• Prevalence of carotid canal dehiscence in the human middle ear: A report of 1000 temporal bonesMoreano E, Paparella M, Zelterman D, Goycoolea M. Prevalence of carotid canal dehiscence in the human middle ear: A report of 1000 temporal bones. The Laryngoscope 1994, 104: 612-618. PMID: 8189992, DOI: 10.1002/lary.5541040515.
• Piecewise exponential survival curves with smooth transitionsZelterman D, Grambsch P, Le C, Z. J, Curtsinger J. Piecewise exponential survival curves with smooth transitions. Mathematical Biosciences 1994, 120: 233-250. PMID: 8204986, DOI: 10.1016/0025-5564(94)90054-x.
• Fisher'S Exact Test of Mutual Independence for 2 X 2 X 2 Cross-Classification TablesMielke P, Berry K, Zelterman D. Fisher'S Exact Test of Mutual Independence for 2 X 2 X 2 Cross-Classification Tables. Educational And Psychological Measurement 1994, 54: 110-114. DOI: 10.1177/0013164494054001014.
• Prevalence of facial canal dehiscence and of persistent stapedial artery in the human middle ear: A report of 1000 temporal bonesMoreano E, Paparella M, Zelterman D, Goycoolea M. Prevalence of facial canal dehiscence and of persistent stapedial artery in the human middle ear: A report of 1000 temporal bones. The Laryngoscope 1994, 104: 309-320. PMID: 8127188, DOI: 10.1288/00005537-199403000-00012.
• A Semiparametric Bootstrap Technique for Simulating Extreme Order StatisticsZelterman D. A Semiparametric Bootstrap Technique for Simulating Extreme Order Statistics. Journal Of The American Statistical Association 1993, 88: 477-485. DOI: 10.1080/01621459.1993.10476298.
• Generalized logistic models for low—dose response dataDevidas M, George E, Zelterman D. Generalized logistic models for low—dose response data. Statistics In Medicine 1993, 12: 881-892. PMID: 8327804, DOI: 10.1002/sim.4780120907.
• Symptomatic versus asymptomatic endolymphatic hydrops: A histopathologic comparisonSperling N, Paparella M, Yoon T, Zelterman D. Symptomatic versus asymptomatic endolymphatic hydrops: A histopathologic comparison. The Laryngoscope 1993, 103: 277-285. PMID: 8441315, DOI: 10.1288/00005537-199303000-00007.
• The effects of school-based health clinics in St. Paul on school-wide birthrates.Kirby D, Resnick M, Downes B, Kocher T, Gunderson P, Potthoff S, Zelterman D, Blum R. The effects of school-based health clinics in St. Paul on school-wide birthrates. Perspectives On Sexual And Reproductive Health 1993, 25: 12-6. PMID: 8432371, DOI: 10.2307/2135987.
• Evaluation of Staging Systems for Colorectal CancerLe C, Grambsch P, Zelterman D, Lindgren B. Evaluation of Staging Systems for Colorectal Cancer. Biometrical Journal 1993, 35: 701-705. DOI: 10.1002/bimj.4710350607.
• Mechanisms of Retraction Pocket Formation in the Pediatric Tympanic MembraneRuah C, Schachern P, Paparella M, Zelterman D. Mechanisms of Retraction Pocket Formation in the Pediatric Tympanic Membrane. JAMA Otolaryngology - Head & Neck Surgery 1992, 118: 1298-1305. PMID: 1449688, DOI: 10.1001/archotol.1992.01880120024005.
• Longitudinal study of psychotropic drug use by elderly nursing home residents.Garrard J, Dunham T, Makris L, Cooper S, Heston L, Ratner E, Zelterman D, Kane R. Longitudinal study of psychotropic drug use by elderly nursing home residents. Journal Of Gerontology 1992, 47: m183-8. PMID: 1358936, DOI: 10.1093/geronj/47.6.m183.
• Inadequate Treatment of Depressed Nursing Home ElderlyHeston L, Garrard J, Makris L, Kane R, Cooper S, Dunham T, Zelterman D. Inadequate Treatment of Depressed Nursing Home Elderly. Journal Of The American Geriatrics Society 1992, 40: 1117-1122. PMID: 1401696, DOI: 10.1111/j.1532-5415.1992.tb01800.x.
• A statistical distribution with an unbounded hazard function and its application to a theory from demography.Zelterman D. A statistical distribution with an unbounded hazard function and its application to a theory from demography. Biometrics 1992, 48: 807-18. PMID: 1420843, DOI: 10.2307/2532346.
• Morphologic scales and relative distances between lesions identified on Papanicolaou smears.Okagaki T, Lau M, Brooker D, Zelterman D. Morphologic scales and relative distances between lesions identified on Papanicolaou smears. Analytical And Quantitative Cytology And Histology 1992, 14: 335-40. PMID: 1388571.
• Indicator models in social mobility tablesZelterman D, Youn T. Indicator models in social mobility tables. Computational Statistics & Data Analysis 1992, 14: 39-53. DOI: 10.1016/0167-9473(92)90080-y.
• Information, discrimination and divergence in cytology. VI. Biases and errors of measurement in small samples.Okagaki T, Lau M, Zelterman D. Information, discrimination and divergence in cytology. VI. Biases and errors of measurement in small samples. Analytical And Quantitative Cytology And Histology 1992, 14: 238-44. PMID: 1418275.
• Goodness of Fit Tests for Proportional Hazards Regression ModelsLe C, Zelterman D, Le C. Goodness of Fit Tests for Proportional Hazards Regression Models. Biometrical Journal 1992, 34: 557-566. DOI: 10.1002/bimj.4710340505.
• Bootstrap Methods for Extreme Order StatisticsZelterman D, Lindgren T. Bootstrap Methods for Extreme Order Statistics. 1992, 580-582. DOI: 10.1007/978-1-4612-2856-1_105.
• RE: “THE IMPACT OF DIETARY MEASUREMENT ERROR ON PLANNING SAMPLE SIZE REQUIRED IN A COHORT STUDY”Kushi L, Zelterman D, Jacobs D, Potter J. RE: “THE IMPACT OF DIETARY MEASUREMENT ERROR ON PLANNING SAMPLE SIZE REQUIRED IN A COHORT STUDY”. American Journal Of Epidemiology 1991, 134: 1470-1472. PMID: 1776623, DOI: 10.1093/oxfordjournals.aje.a116057.
• Homogeneity of the relative risk in cohort studiesLe C, Lindgren B, Zelterman D, Umen A. Homogeneity of the relative risk in cohort studies. Statistics In Medicine 1991, 10: 1267-1272. PMID: 1925157, DOI: 10.1002/sim.4780100809.
• Is Bias Inherent in HCFA-Sponsored Research?-ReplyGarrard J, Kane R, Makris L, Dunham T, Heston L, Cooper S, Ratner E, Zelterman D. Is Bias Inherent in HCFA-Sponsored Research?-Reply. JAMA 1991, 266: 64-64. DOI: 10.1001/jama.1991.03470010067022.
• Middle Ear Fluid Lysozyme Source in Experimental Pneumococcal Otitis MediaNonomura N, Giebink G, Harada T, Zelterman D, Juhn S. Middle Ear Fluid Lysozyme Source in Experimental Pneumococcal Otitis Media. Annals Of Otology Rhinology & Laryngology 1991, 100: 593-596. PMID: 2064274, DOI: 10.1177/000348949110000715.
• Tests of homogeneity for the relative risk in multiply-matched case-control studies.Zelterman D, Le C. Tests of homogeneity for the relative risk in multiply-matched case-control studies. Biometrics 1991, 47: 751-5. PMID: 1912269, DOI: 10.2307/2532162.
• Age-Related Morphologic Changes in the Human Tympanic Membrane: A Light and Electron Microscopic StudyRuah C, Schachern P, Zelterman D, Paparella M, Yoon T. Age-Related Morphologic Changes in the Human Tympanic Membrane: A Light and Electron Microscopic Study. JAMA Otolaryngology - Head & Neck Surgery 1991, 117: 627-634. PMID: 2036184, DOI: 10.1001/archotol.1991.01870180063013.
• Early Biochemical Events in Pneumococcal Otitis Media: Arachidonic Acid Metabolites in Middle Ear FluidNonomura N, Giebink G, Harada T, Zelterman D, Juhn S. Early Biochemical Events in Pneumococcal Otitis Media: Arachidonic Acid Metabolites in Middle Ear Fluid. Annals Of Otology Rhinology & Laryngology 1991, 100: 385-388. PMID: 1850967, DOI: 10.1177/000348949110000507.
• Evaluation of Neuroleptic Drug Use by Nursing Home Elderly Under Proposed Medicare and Medicaid RegulationsGarrard J, Makris L, Dunham T, Heston L, Cooper S, Ratner E, Zelterman D, Kane R. Evaluation of Neuroleptic Drug Use by Nursing Home Elderly Under Proposed Medicare and Medicaid Regulations. JAMA 1991, 265: 463-467. PMID: 1670645, DOI: 10.1001/jama.1991.03460040039025.
• Information, discrimination and divergence in cytology. II. Total discrimination as a measure of performance.Okagaki T, Zelterman D. Information, discrimination and divergence in cytology. II. Total discrimination as a measure of performance. Acta Cytologica 1991, 35: 25-9. PMID: 1994629.
• Information, discrimination and divergence in cytology. III. Optimization of classification of Papanicolaou smears.Okagaki T, Fujimura M, Zelterman D. Information, discrimination and divergence in cytology. III. Optimization of classification of Papanicolaou smears. Acta Cytologica 1991, 35: 30-4. PMID: 1994631.
• Information, discrimination and divergence in cytology. IV. Quality control in diagnostic cytology.Okagaki T, Fujimura M, Brooker D, McIntosh L, Zelterman D. Information, discrimination and divergence in cytology. IV. Quality control in diagnostic cytology. Acta Cytologica 1991, 35: 35-9. PMID: 1994632.
• Smooth nonparametric estimation of the quantile functionZelterman D. Smooth nonparametric estimation of the quantile function. Journal Of Statistical Planning And Inference 1990, 26: 339-352. DOI: 10.1016/0378-3758(90)90136-i.
• Information, discrimination and divergence in cytology. I. Theoretical aspects and definitions.Okagaki T, Zelterman D. Information, discrimination and divergence in cytology. I. Theoretical aspects and definitions. Analytical And Quantitative Cytology And Histology 1990, 12: 342-7. PMID: 2268389.
• On tests for qualitative interactionsZelterman D. On tests for qualitative interactions. Statistics & Probability Letters 1990, 10: 59-63. DOI: 10.1016/0167-7152(90)90112-k.
• Testing for central mixtures of compartment model parametersZelterman D. Testing for central mixtures of compartment model parameters. Statistics In Medicine 1989, 8: 1011-1021. PMID: 2799120, DOI: 10.1002/sim.4780080811.
• Order statistics of the generalized logistic distributionZelterman D. Order statistics of the generalized logistic distribution. Computational Statistics & Data Analysis 1988, 7: 69-77. DOI: 10.1016/0167-9473(88)90016-3.
• Likelihood ratio tests for central mixturesZelterman D. Likelihood ratio tests for central mixtures. Statistics & Probability Letters 1988, 6: 275-279. DOI: 10.1016/0167-7152(88)90074-0.
• Homogeneity Tests against Central-Mixture AlternativesZelterman D, Chen C. Homogeneity Tests against Central-Mixture Alternatives. Journal Of The American Statistical Association 1988, 83: 179-182. DOI: 10.1080/01621459.1988.10478585.
• Robust estimation in truncated discrete distributions with application to capture-recapture experimentsZelterman D. Robust estimation in truncated discrete distributions with application to capture-recapture experiments. Journal Of Statistical Planning And Inference 1988, 18: 225-237. DOI: 10.1016/0378-3758(88)90007-9.
• Goodness-of-Fit Tests for Large Sparse Multinomial DistributionsZelterman D. Goodness-of-Fit Tests for Large Sparse Multinomial Distributions. Journal Of The American Statistical Association 1987, 82: 624-629. DOI: 10.1080/01621459.1987.10478475.
• Parameter estimation in the generalized logistic distributionZelterman D. Parameter estimation in the generalized logistic distribution. Computational Statistics & Data Analysis 1987, 5: 177-184. DOI: 10.1016/0167-9473(87)90013-2.
• The log-likelihood ratio for sparse multinomial mixturesZelterman D. The log-likelihood ratio for sparse multinomial mixtures. Statistics & Probability Letters 1986, 4: 95-99. DOI: 10.1016/0167-7152(86)90024-6.
• Approximating the distribution of goodness of fit tests for discrete dataZelterman D. Approximating the distribution of goodness of fit tests for discrete data. Computational Statistics & Data Analysis 1984, 2: 207-214. DOI: 10.1016/0167-9473(84)90012-4.
• Differences in biological activity among batches of lyophilized tice Bacillus Calmette-Guérin and their association with clinical course in Stage I lung cancer.Bennett J, Gruft H, McKneally M, Zelterman D, Crispen R. Differences in biological activity among batches of lyophilized tice Bacillus Calmette-Guérin and their association with clinical course in Stage I lung cancer. Cancer Research 1983, 43: 4183-90. PMID: 6347367.
• Ontogenesis of spontaneous activity and habituation of activity in the rat pupShaywitz B, Gordon J, Klopper J, Zelterman D, Irvine J. Ontogenesis of spontaneous activity and habituation of activity in the rat pup. Developmental Psychobiology 1979, 12: 359-367. PMID: 456762, DOI: 10.1002/dev.420120410.
• The effect of 6-hydroxydopamine on habituation of activity in the developing rat pupShaywitz B, Gordon J, Klopper J, Zelterman D. The effect of 6-hydroxydopamine on habituation of activity in the developing rat pup. Pharmacology Biochemistry And Behavior 1977, 6: 391-396. PMID: 882577, DOI: 10.1016/0091-3057(77)90175-7.